Sepsis-driven metabolic reprogramming shapes cancer immunotherapy efficacy, metastatic potential, and drug sensitivity
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sepsis and cancer have a complex relationship, where sepsis alters metabolism, hindering cancer immunotherapy and promoting metastasis. Integrated treatments targeting metabolism, immunity, and the microbiome are crucial for better patient outcomes.
Area Of Science
- Oncology
- Immunology
- Metabolic Research
Background
- Sepsis and cancer exhibit a complex bidirectional interaction significantly affecting patient prognosis.
- Metabolic reprogramming is a critical factor mediating the interplay between sepsis and cancer.
- Sepsis-induced immune dysregulation and metabolic alterations promote immunosuppression, tumor progression, metastasis, and immunotherapy resistance.
Purpose Of The Study
- To explore the impact of sepsis-driven metabolic reprogramming on cancer immunotherapy and metastasis.
- To provide a foundation for developing future integrated treatment strategies for patients with both sepsis and cancer.
- To highlight the need for personalized care through biomarker identification.
Main Methods
- Review of current literature on sepsis-cancer interactions, metabolic reprogramming, and immunotherapy.
- Analysis of molecular insights, immunotherapy efficacy, and drug sensitivity in the context of sepsis.
- Exploration of potential therapeutic strategies integrating metabolic interventions and antimicrobial approaches.
Main Results
- Sepsis significantly impacts cancer progression by promoting immunosuppression, tumor growth, metastasis, and resistance to immunotherapy through metabolic reprogramming.
- Cancer patients, particularly those on immunosuppressive therapies, are at higher risk of sepsis, leading to complicated treatment and poorer outcomes.
- An integrated therapeutic approach is essential, combining immunotherapy, metabolic interventions, and antimicrobial strategies.
Conclusions
- Sepsis-driven metabolic reprogramming critically influences cancer immunotherapy and metastasis.
- Integrated treatment strategies are necessary to address the complex interplay between sepsis, cancer metabolism, and immunity.
- Future research should focus on developing precise therapies that modulate metabolism, immunity, and the microbiome for improved patient outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...